Engineered immune cells take on stubborn blood disorder

NCT ID NCT07416032

Not yet recruiting Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial will test a new type of CAR T-cell therapy, called QT-019C, in 27 adults with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The therapy uses donor-derived immune cells engineered to target two proteins (CD19 and BCMA) on the cells driving the disease. The main goals are to check safety and see if it can raise platelet counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Universal allogeneic CAR T-cells targeting CD19 and BCMA (QT-019C)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat immune thrombocytopenia, potentially reducing bleeding risk.
What could go wrong: This is a very early, small trial (27 people) focused on safety. The therapy may not work, and side effects like cytokine release syndrome or neurological issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.